Global Pharmacovigilance Rulebook: How FDA, EMA GVP and MHRA Fit Together Global Pharmacovigilance Rulebook: How FDA, EMA GVP and MHRA Fit Together In the complex landscape of pharmaceutical and biotechnology industries, the significance of pharmacovigilance (PV) cannot be overstated. Regulatory Affairs professionals must navigate an intricate web of guidelines and regulations to ensure drug safety and compliance with global standards. This article offers a comprehensive breakdown of the pharmacovigilance service provider framework as it pertains to the FDA, EMA, MHRA, and related authorities, aimed specifically at Regulatory Affairs and CMC teams in the US and EU. Context of Pharmacovigilance Pharmacovigilance…

ICH E2 Guidance in Real Life: What Safety and RA Teams Actually Do ICH E2 Guidance in Real Life: What Safety and RA Teams Actually Do Context Pharmacovigilance (PV) is a critical component of drug development and post-market surveillance that aims to ensure the safety of pharmaceutical products. It involves the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Regulatory Affairs (RA) teams, alongside Clinical, Quality Assurance (QA), and Commercial teams, play a pivotal role in ensuring compliance with pharmacovigilance services and guidelines, particularly as outlined in the ICH E2 series. Understanding these regulations and…

Building a Coherent Global PV Framework Across US, EU and UK Building a Coherent Global PV Framework Across US, EU and UK Context Pharmacovigilance (PV) is an essential component of drug safety and risk management, ensuring that the benefits of pharmaceutical products outweigh their risks. The goal of a Pharmacovigilance system is to enhance patient safety and ensure that pharmaceutical companies comply with various regulatory requirements set by health authorities globally. The frameworks established by the FDA, EMA, and MHRA for pharmacovigilance are designed to optimize the collection, analysis, and reporting of adverse drug reactions (ADRs) and other safety-related information….

Key Differences Between FDA, EMA and MHRA Pharmacovigilance Expectations Key Differences Between FDA, EMA and MHRA Pharmacovigilance Expectations Context Pharmacovigilance (PV) is an essential component of drug safety and risk management across global markets. Regulatory compliance with pharmacovigilance guidelines is crucial for pharmaceutical companies. In the United States, the Food and Drug Administration (FDA), in Europe, the European Medicines Agency (EMA), and in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) set the standards for PV practices. Understanding the differences and similarities in the regulatory expectations of these key entities is vital for ensuring compliance and safeguarding…

How EMA GVP Modules Interact with Core PV Processes How EMA GVP Modules Interact with Core PV Processes The global pharmaceutical landscape is characterized by stringent safety regulations and risk management protocols. Among these, pharmacovigilance (PV) plays a pivotal role in monitoring and ensuring drug safety. The European Medicines Agency (EMA) has developed Good Pharmacovigilance Practices (GVP) modules that provide a structured approach to pharmacovigilance compliance. This article aims to explore the interaction between EMA GVP modules and core pharmacovigilance processes, providing insights for regulatory affairs (RA) professionals in the US, UK, and EU. Regulatory Context Pharmacovigilance refers to the…

Operationalising ICH E2A–E2F: From Guidelines to SOPs and Training Operationalising ICH E2A–E2F: From Guidelines to SOPs and Training In the context of pharmacovigilance, effective compliance with ICH E2A to E2F guidelines is essential for ensuring drug safety and risk management. For professionals in Regulatory Affairs, CMC, and Labelling teams, understanding how to operationalize these guidelines into standard operating procedures (SOPs) and training is critical for maintaining product compliance consulting across various global markets. This regulatory explainer manual provides an extensive overview of relevant regulations, guidelines, and agency expectations pertaining to global pharmacovigilance compliance. Context The ICH E2 series, which encompasses…

Governance Structures That Keep Global PV Frameworks Aligned Governance Structures That Keep Global PV Frameworks Aligned Context Pharmacovigilance (PV) plays a critical role in monitoring the safety of medications and ensuring their benefits outweigh risks post-marketing. Governance structures for pharmacovigilance ensure that organizations comply with various regulatory frameworks across the globe—particularly in the US, UK, and EU. These frameworks cover a diverse array of legal requirements, and provide guidelines mandated by authorities such as the FDA, EMA, and MHRA. Adherence to global pharmacovigilance regulations not only ensures drug safety compliance but also fortifies public health. Companies must bolster their practice…

Using Regulatory Intelligence to Track PV Rule Changes Worldwide Using Regulatory Intelligence to Track PV Rule Changes Worldwide In a rapidly evolving pharmaceutical landscape, the necessity for stringent regulatory affairs compliance becomes even more critical. Regulatory intelligence plays a vital role in ensuring that drug safety and risk management protocols align with varying guidelines, particularly in pharmacovigilance (PV) efforts across the US, UK, and EU regions. This article seeks to elucidate the critical elements of regulatory affairs compliance within the context of the global pharmacovigilance frameworks, specifically focusing on FDA, EMA GVP, and MHRA regulations alongside ICH E2 guidelines. Regulatory…

Case Studies: When Global PV Frameworks Were Not Aligned—and What Happened Case Studies: When Global PV Frameworks Were Not Aligned—and What Happened Context In the field of Regulatory Affairs (RA), the term “compliance” encompasses a multitude of domains, most importantly, pharmacovigilance (PV) and drug safety systems. With significant efforts devoted to ensuring drug safety and risk management, it is crucial for healthcare professionals and pharmaceutical companies to understand how discrepancies in global PV frameworks can lead to compliance challenges. This article explores case studies that highlight misalignments between various regulatory standards, particularly those of the FDA (United States), the EMA…

How RA and PV Share Ownership of Benefit–Risk Under Global Rules How RA and PV Share Ownership of Benefit–Risk Under Global Rules In the highly regulated landscape of the pharmaceutical and biotechnology industries, the intersection of Regulatory Affairs (RA) and Pharmacovigilance (PV) plays a critical role in ensuring drug safety and compliance. Understanding how these functions interact within the framework of global regulations is essential for professionals involved in the CMC and labelling teams across the US, UK, and EU. This article will delve into the intricate relationship between RA and PV, highlighting relevant regulations, guidelines, documentation practices, and common…